Download PDF
Thromb Haemost 2022; 122(03): 320-328
DOI: 10.1055/a-1496-8527
Review Article

Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review

Akitada Ichinose
1   Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan
2   The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Japan
,
Tsukasa Osaki
1   Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan
2   The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Japan
3   Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Iida-Nishi, Yamagata, Japan
,
Masayoshi Souri
1   Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan
2   The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Japan
3   Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Iida-Nishi, Yamagata, Japan
› Author Affiliations Funding This study was supported in part by research aids from the Japanese Ministry of Health, Labor, and Welfare (MHLW).
› Further Information
   Permissions and Reprints

Abstract

Coagulation factor X (F10) amplifies the clotting reaction in the middle of the coagulation cascade, and thus F10 deficiency leads to a bleeding tendency. Isolated acquired F10 deficiency is widely recognized in patients with immunoglobulin light-chain amyloidosis or plasma cell dyscrasias. However, its occurrence as an autoimmune disorder is extremely rare. The Japanese Collaborative Research Group has been conducting a nationwide survey on autoimmune coagulation factor deficiencies (AiCFDs) starting in the last decade; we recently identified three patients with autoimmune F10 deficiency (AiF10D). Furthermore, an extensive literature search was performed, confirming 26 AiF10D and 28 possible cases. Our study revealed that AiF10D patients were younger than patients with other AiCFDs; AiF10D patients included children and were predominantly male. AiF10D was confirmed as a severe type of bleeding diathesis, although its mortality rate was not high. As AiF10D patients showed only low F10 inhibitor titers, they were considered to have nonneutralizing anti-F10 autoantibodies rather than their neutralizing counterparts. Accordingly, immunological anti-F10 antibody detection is highly recommended. Hemostatic and immunosuppressive therapies may help arrest bleeding and eliminate anti-F10 antibodies, leading to a high recovery rate. However, further investigation is necessary to understand the basic characteristics and proper management of AiF10D owing to the limited number of patients.

Keywords

coagulation - factor X - bleeding disorders - autoantibodies - nonneutralizing

Author Contributions

A.I. initiated and designed the study, extracted data, wrote, edited, and proofread the manuscript. T.O. conducted experimental examinations, statistical analyses, and proofread the manuscript. M.S. performed experimental examinations, and proofread the manuscript.


Supplementary Material



Publication History

Received: 01 March 2021

Accepted: 27 April 2021

Accepted Manuscript online:
30 April 2021

Article published online:
15 June 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Uprichard J, Perry DJ. Factor X deficiency. Blood Rev 2002; 16 (02) 97-110
    CrossrefPubMedGoogle Scholar
  • 2 Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost 2009; 35 (04) 407-415
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Ichinose A. Diagnosis and treatment of acquired factor XIII/13 deficiencies: for all doctors treating the MHLW's designated intractable diseases [in Japanese]. Rinsho Ketsueki 2015; 56 (10) 2110-2122
    PubMedGoogle Scholar
  • 4 Ichinose A. Immune-mediated acquired coagulation factor deficiencies: state-of-the-art in diagnosis and management [in Japanese]. Rinsho Ketsueki 2019; 60 (06) 667-679
    PubMedGoogle Scholar
  • 5 Ichinose A. The present condition of and clinical guidance for autoimmune coagulation factor deficiencies in Japan. Jpn J Thromb Haemost 2018; 29: 251-261
    CrossrefPubMedGoogle Scholar
  • 6 Lee G, Duan-Porter W, Metjian AD. Acquired, non-amyloid related factor X deficiency: review of the literature. Haemophilia 2012; 18 (05) 655-663
    CrossrefPubMedGoogle Scholar
  • 7 Mori M, Mochizuki K, Souri M. et al. Complete remission in a bleeding patient with idiopathic autoimmune factor X deficiency caused by non-neutralizing anti-factor X autoantibody. Haemophilia 2019; 25 (02) e106-e109
    CrossrefPubMedGoogle Scholar
  • 8 Ichikawa S, Saito K, Fukuhara N. et al. Successful treatment of life-threatening bleeding caused by acquired factor X deficiency associated with respiratory infection. Intern Med 2020; 59 (10) 1303-1308
    CrossrefPubMedGoogle Scholar
  • 9 Fujii S, Sasada Y, Kunikado R. et al. Experience with administration of cryoprecipitate to an elderly patient with undetermined type of bleeding tendency. Paper presented at: The 64th Annual Meeting of the Kinki Branch of the Japan Society of Transfusion Medicine and Cell Therapy; November 21, 2020; Nara, Japan. [Abstract]
    PubMedGoogle Scholar
  • 10 Rochanda L, Del Zoppo GJ, Feinstein DI, Liebman HA. Approach to the treatment, characterization and diagnosis of an acquired auto-antibody directed against factors prothrombin, factor X and factor IX: a case report and review of the literature. Haemophilia 2012; 18 (01) 102-107
    CrossrefPubMedGoogle Scholar
  • 11 White CF, Davis WM, Desai MH. Acquired; transient factor X deficiency in a patient with severe burns. J Burn Care Rehabil 1984; 5 (03) 247-249
    CrossrefPubMedGoogle Scholar
  • 12 Tsukai K, Shimada K, Masuda H, Suehisa H, Motoi S. A patient with factor 10 deficiency. Jpn J Med Technol 1987; 6: 398
    PubMedGoogle Scholar
  • 13 Collins PW, Hirsch S, Baglin TP. et al; UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007; 109 (05) 1870-1877
    CrossrefPubMedGoogle Scholar
  • 14 Ichinose A. ; Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: a summary of 93 patients. Blood Rev 2017; 31 (01) 37-45
    CrossrefPubMedGoogle Scholar
  • 15 Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol 2000; 110 (02) 454-460
    CrossrefPubMedGoogle Scholar
  • 16 Choufani EB, Sanchorawala V, Ernst T. et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97 (06) 1885-1887
    CrossrefPubMedGoogle Scholar
  • 17 Arahata M, Takamatsu H, Morishita E. et al. Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid. Int J Hematol 2020; 111 (04) 550-558
    CrossrefPubMedGoogle Scholar
  • 18 Landgren O, Kyle RA, Pfeiffer RM. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113 (22) 5412-5417
    CrossrefPubMedGoogle Scholar
  • 19 Dispenzieri A, Katzmann JA, Kyle RA. et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375 (9727): 1721-1728
    CrossrefPubMedGoogle Scholar
  • 20 Kyle RA, Rajkumar SV. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park) 2011; 25 (07) 578-586
    PubMedGoogle Scholar
  • 21 Gertz MA. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J 2018; 8: 44
    CrossrefPubMedGoogle Scholar
  • 22 Manabe M, Tsujimaki M, Kakuta S, Nagumo M. Acquired factor X deficiency: an experience with multiple tooth extraction. J Oral Maxillofac Surg 1993; 51 (08) 922-924
    CrossrefPubMedGoogle Scholar
  • 23 De Jager E, Bieger R, Castel A, Kluin PM. Successful treatment of an acquired haemorrhagic diathesis due to factor X deficiency with chemotherapy. Eur J Haematol 2001; 66 (05) 352-354
    CrossrefPubMedGoogle Scholar
  • 24 Koyama S, Shirasaki R, Tashiro H. et al. A case of lymphoproliferative disorder with marked bleeding tendency due to acquired factor 10 deficiency. Paper presented at: The 559th Kanto Regional Association of the Japanese Society of Internal Medicine; December 13, 2008; Tokyo, Japan. [Abstract]
    PubMedGoogle Scholar
  • 25 Shirasaki R, Oka Y, Sugao T. et al. Splenic marginal zone lymphoma complicated with acquired factor X deficiency. Rinsho Ketsueki 2009; 50 (04) 321-322
    PubMedGoogle Scholar
  • 26 Tashiro H, Shirasaki R, Watanabe M, Kawasugi K, Takahashi Y, Shirafuji N. Direct Factor X sequestration by systemic amyloid light-chain amyloidosis. Clin Case Rep 2018; 6 (03) 513-515
    CrossrefPubMedGoogle Scholar
  • 27 Siragusa S, Morice W, Gertz MA. et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol 2011; 90 (01) 101-106
    CrossrefPubMedGoogle Scholar
  • 28 McCausland KL, White MK, Guthrie SD. et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient 2018; 11 (02) 207-216
    CrossrefPubMedGoogle Scholar
  • 29 Furie B, Voo L, McAdam KP, Furie BC. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 1981; 304 (14) 827-830
    CrossrefPubMedGoogle Scholar
  • 30 Peyvandi F, Palla R, Menegatti M. et al; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10 (04) 615-621
    CrossrefPubMedGoogle Scholar
  • 31 Baudo F, Collins P, Huth-Kühne A. et al; EACH2 registry contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120 (01) 39-46
    CrossrefPubMedGoogle Scholar
  • 32 Broze Jr GJ. An acquired, calcium-dependent, factor X inhibitor. Blood Cells Mol Dis 2014; 52 (2–3): 116-120
    CrossrefPubMedGoogle Scholar
  • 33 Gollard R, Rahman S, Ratnasabapathy R. Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male. Acta Haematol 2013; 129 (01) 40-44
    CrossrefPubMedGoogle Scholar
  • 34 Rao LV, Zivelin A, Iturbe I, Rapaport SI. Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody. Thromb Haemost 1994; 72 (03) 363-371
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Matsunaga AT, Shafer FE. An acquired inhibitor to factor X in a pediatric patient with extensive burns. J Pediatr Hematol Oncol 1996; 18 (02) 223-226
    CrossrefPubMedGoogle Scholar
  • 36 Tone KJ, James TE, Fergusson DA. et al. Acquired factor XIII inhibitor in hospitalized and perioperative patients: a systematic review of case reports and case series. Transfus Med Rev 2016; 30 (03) 123-131
    CrossrefPubMedGoogle Scholar
  • 37 Ashrani AA, Aysola A, Al-Khatib H, Nichols WL, Key NS. Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications. Br J Haematol 2003; 121 (04) 639-642
    CrossrefPubMedGoogle Scholar
  • 38 Haberal M, Basaran O, Sakallioğlu AE, Kesik E, Alioğlu B, Ozbek N. Acquired-transient factor X deficiency associated with anticardiolipin antibodies in a child with extensive burns. J Burn Care Res 2006; 27 (01) 113-116
    CrossrefPubMedGoogle Scholar
  • 39 Pengo V, Tripodi A, Reber G. et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
    CrossrefPubMedGoogle Scholar
  • 40 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
    CrossrefPubMedGoogle Scholar
  • 41 Ortel TL. Laboratory diagnosis of the lupus anticoagulant. Curr Rheumatol Rep 2012; 14 (01) 64-70
    CrossrefPubMedGoogle Scholar
  • 42 Hoxha A, Banzato A, Ruffatti A, Pengo V. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev 2017; 16 (02) 173-178
    CrossrefPubMedGoogle Scholar
  • 43 Lankiewicz MW, Bell WR. A unique circulating inhibitor with specificity for coagulation factor X. Am J Med 1992; 93 (03) 343-346
    CrossrefPubMedGoogle Scholar
  • 44 Smith SV, Liles DK, White II GC, Brecher ME. Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy. Am J Hematol 1998; 57 (03) 245-252
    CrossrefPubMedGoogle Scholar
  • 45 Meenhuis A, van Vliet R, Hudig F, Ypma PF, Schipperus MR, Hollestelle MJ. Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma. Clin Case Rep 2015; 3 (07) 587-593
    CrossrefPubMedGoogle Scholar
  • 46 Ishiguro K, Hayashi T, Yokoyama Y. et al. Elevation of Plasmin-α2-plasmin inhibitor complex predicts the diagnosis of systemic AL amyloidosis in patients with monoclonal protein. Intern Med 2018; 57 (06) 783-788
    CrossrefPubMedGoogle Scholar
  • 47 Bouma B, Maas C, Hazenberg BP, Lokhorst HM, Gebbink MF. Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost 2007; 5 (06) 1139-1142
    CrossrefPubMedGoogle Scholar
  • 48 Dejhansathit S, Suvannasankha A. Acquired factor X deficiency in patients with primary light chain amyloidosis. J Investig Med High Impact Case Rep 2019; 7: 2324709619832332
    CrossrefPubMedGoogle Scholar
  • 49 Ness PM, Hymas PG, Gesme D, Perkins HA. An unusual factor-X inhibitor in leprosy. Am J Hematol 1980; 8 (04) 397-402
    CrossrefPubMedGoogle Scholar
  • 50 Shapiro A. Plasma-derived human factor X concentrate for on-demand and perioperative treatment in factor X-deficient patients: pharmacology, pharmacokinetics, efficacy, and safety. Expert Opin Drug Metab Toxicol 2017; 13 (01) 97-104
    CrossrefPubMedGoogle Scholar
  • 51 Ochi S, Takeyama M, Shima M, Nogami K. Plasma-derived factors VIIa and X mixtures (Byclot®) significantly improve impairment of coagulant potential ex vivo in plasmas from acquired hemophilia A patients. Int J Hematol 2020; 111 (06) 779-785
    CrossrefPubMedGoogle Scholar
  • 52 Mulhare PE, Tracy PB, Golden EA, Branda RF, Bovill EG. A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X. Am J Clin Pathol 1991; 96 (02) 196-200
    CrossrefPubMedGoogle Scholar
  • 53 Aylı M, Dağdaş S, Yılmaz S. Isolated acquired FX deficiency: a case report. Turk J Haematol 2000; 17 (01) 29-32
    PubMedGoogle Scholar